Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the Litx™ treatment is safe and effective
in treating inoperable hepatocellular carcinoma (HCC).
Litx™ is an integrated treatment system comprising an intravenously administered
photosensitizing agent, Talaporfin Sodium (LS11), that is activated by non-coherent light
generated inside the tumor by an implanted light emitting diode (LED) array light source.